NASDAQ:EVGN Evogene (EVGN) Stock Price, News & Analysis $0.33 -0.03 (-7.62%) Closing price 11/5/2026 03:55 PM EasternExtended Trading$0.30 -0.03 (-8.98%) As of 11/5/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOwnershipSEC Filings About Evogene Stock (NASDAQ:EVGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Evogene alerts:Sign Up Key Stats Today's Range$0.30▼$0.3450-Day Range$0.33▼$0.5552-Week Range$0.30▼$1.28Volume7.16 million shsAverage Volume43,924 shsMarket Capitalization$2.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Evogene Ltd. (NASDAQ: EVGN) is an Israel-based computational biology company that develops technologies and products designed to improve human health, agriculture and sustainability. The company uses artificial intelligence, machine learning and biological data analysis through its Computational Predictive Biology platform to identify and develop solutions based on biological mechanisms. Evogene has built a portfolio of subsidiaries and business units focused on areas including agricultural biologicals, crop protection, microbiome-based therapeutics and medical cannabis. Its agricultural activities include the discovery and development of biological products such as bio-stimulants and biopesticides, while its human-health programs focus on microbiome-derived therapeutic candidates and related technologies. The company has also pursued collaborations and licensing arrangements with partners in its target markets. Founded in 1998 and headquartered in Rehovot, Israel, Evogene serves global agriculture and life-sciences markets through partnerships, research collaborations and product-development programs. Ofer Haviv, a co-founder of the company, has served as Evogene’s president and chief executive officer.AI Generated. May Contain Errors. Read More Evogene Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreEVGN MarketRank™: 1.33239549839 of 5 starsEvogene scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingEvogene has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageEvogene has only been the subject of 1 research reports in the past 90 days.Read more about Evogene's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Evogene are expected to grow in the coming year, from ($1.10) to ($0.60) per share.Price to Book Value per Share RatioEvogene has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Evogene's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.79% of the float of Evogene has been sold short.Short Interest Ratio / Days to CoverEvogene has a short interest ratio ("days to cover") of 0.26, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evogene has recently decreased by 93.15%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvogene does not currently pay a dividend.Dividend GrowthEvogene does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Evogene this week, compared to 2 articles on an average week. Company Ownership3.2 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $294,400.00 in company stock, which represents 10.2432% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Evogene insiders have bought more of their company's stock than they have sold. Specifically, they have bought $294,400.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders7.40% of the stock of Evogene is held by insiders.Percentage Held by Institutions10.40% of the stock of Evogene is held by institutions.Read more about Evogene's insider trading history. Receive EVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EVGN Stock News HeadlinesEvogene Schedules Third Quarter 2026 Financial Results ReleaseNovember 5 at 7:00 AM | prnewswire.comEvogene Targets Acute GVHD With AI-Driven Drug Discovery ProgramOctober 29, 2026 | rttnews.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets. | Weiss Ratings (Ad)Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery ProgramOctober 28, 2026 | prnewswire.comEvogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in SpainOctober 26, 2026 | prnewswire.comEvogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeILOctober 20, 2026 | prnewswire.comEvogene consensus price target decreased by 14.04% to ₪590.96October 9, 2026 | msn.comEvogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of DirectorsOctober 6, 2026 | prnewswire.comSee More Headlines EVGN Stock Analysis - Frequently Asked Questions How have EVGN shares performed this year? Evogene's stock was trading at $1.10 at the beginning of the year. Since then, EVGN shares have decreased by 70.0% and is now trading at $0.3296. How were Evogene's earnings last quarter? Evogene Ltd. (NASDAQ:EVGN) released its earnings results on Saturday, May, 16th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.33. The biotechnology company earned $334 thousand during the quarter, compared to the consensus estimate of $350 thousand. Evogene had a negative trailing twelve-month return on equity of 156.53% and a negative net margin of 694.18%. Read the conference call transcript. When did Evogene's stock split? Evogene shares reverse split on Thursday, July 25th 2024.The 1-10 reverse split was announced on Tuesday, July 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Evogene? Shares of EVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evogene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evogene investors own include NIO (NIO), FuelCell Energy (FCEL), Palantir Technologies (PLTR), Tesla (TSLA), Micron Technology (MU), Nano Dimension (NNDM) and NVIDIA (NVDA). Company Calendar Last Earnings5/16/2026Today11/05/2026Next Earnings (Estimated)11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 EVGN's financial health is in the Yellow zone, according to TradeSmith. EVGN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:EVGN CIK1574565 Webwww.evogene.com Phone(728) 931-1900Fax972-8946-6724Employees52Year Founded1999Profitability EPS (Trailing Twelve Months)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.48 million Net Margins-694.18% Pretax Margin-1,230.53% Return on Equity-156.53% Return on Assets-86.80% Debt Debt-to-Equity RatioN/A Current Ratio3.57 Quick Ratio3.54 Sales & Book Value Annual Sales$3.85 million Price / Sales0.75 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book0.24Miscellaneous Outstanding Shares8,720,000Free Float8,073,000Market Cap$2.87 million OptionableNo Data Beta1.46 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:EVGN) was last updated on 11/5/2026 by MarketBeat.com Staff. From Our PartnersI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredCritical SpaceX supplier w/ patented tech trading for $5President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evogene Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evogene With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
